AU2008247603A1 - Use of HDAC inhibitors for the treatment of gastrointestinal cancers - Google Patents

Use of HDAC inhibitors for the treatment of gastrointestinal cancers Download PDF

Info

Publication number
AU2008247603A1
AU2008247603A1 AU2008247603A AU2008247603A AU2008247603A1 AU 2008247603 A1 AU2008247603 A1 AU 2008247603A1 AU 2008247603 A AU2008247603 A AU 2008247603A AU 2008247603 A AU2008247603 A AU 2008247603A AU 2008247603 A1 AU2008247603 A1 AU 2008247603A1
Authority
AU
Australia
Prior art keywords
alkyl
aryl
heteroaryl
arylalkyl
coheterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008247603A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39683987&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008247603(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2008247603A1 publication Critical patent/AU2008247603A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2008247603A 2007-05-04 2008-05-02 Use of HDAC inhibitors for the treatment of gastrointestinal cancers Abandoned AU2008247603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91599607P 2007-05-04 2007-05-04
US60/915,996 2007-05-04
PCT/US2008/062341 WO2008137630A1 (fr) 2007-05-04 2008-05-02 Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux

Publications (1)

Publication Number Publication Date
AU2008247603A1 true AU2008247603A1 (en) 2008-11-13

Family

ID=39683987

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008247603A Abandoned AU2008247603A1 (en) 2007-05-04 2008-05-02 Use of HDAC inhibitors for the treatment of gastrointestinal cancers

Country Status (16)

Country Link
EP (1) EP2142190A1 (fr)
JP (1) JP2010526149A (fr)
KR (1) KR20100016171A (fr)
CN (1) CN101674825A (fr)
AU (1) AU2008247603A1 (fr)
BR (1) BRPI0811112A2 (fr)
CA (1) CA2683554A1 (fr)
CL (1) CL2008001269A1 (fr)
IL (1) IL201318A0 (fr)
MA (1) MA31356B1 (fr)
MX (1) MX2009011692A (fr)
RU (1) RU2009144842A (fr)
TN (1) TN2009000427A1 (fr)
TW (1) TW200908964A (fr)
WO (1) WO2008137630A1 (fr)
ZA (1) ZA200906739B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
MXPA06004735A (es) * 2003-10-27 2006-12-14 S Bio Pte Ltd Hidroxamatos conectados a acilurea y a sulfonilurea.
TW200524575A (en) * 2003-10-27 2005-08-01 S Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
WO2006075165A1 (fr) * 2005-01-13 2006-07-20 Btg International Limited Combinaison de virus oncolytiques a des inhibiteurs d'angiogenese

Also Published As

Publication number Publication date
CN101674825A (zh) 2010-03-17
CL2008001269A1 (es) 2008-12-19
CA2683554A1 (fr) 2008-11-13
BRPI0811112A2 (pt) 2014-12-23
EP2142190A1 (fr) 2010-01-13
MX2009011692A (es) 2009-11-10
TW200908964A (en) 2009-03-01
WO2008137630A1 (fr) 2008-11-13
IL201318A0 (en) 2010-05-31
ZA200906739B (en) 2010-06-30
RU2009144842A (ru) 2011-06-10
TN2009000427A1 (en) 2011-03-31
JP2010526149A (ja) 2010-07-29
KR20100016171A (ko) 2010-02-12
MA31356B1 (fr) 2010-05-03

Similar Documents

Publication Publication Date Title
US20100137398A1 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers
AU2007328281B2 (en) Combination of an HDAC inhibitor and an antimetabolite
JP5876435B2 (ja) 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
AU2008247603A1 (en) Use of HDAC inhibitors for the treatment of gastrointestinal cancers
AU2008260236A1 (en) Use of HDAC inhibitors for the treatment of bone destruction
AU2008204928B2 (en) Formulations of deacetylase inhibitors
AU2008251499A1 (en) Use of HDAC inhibitors for the treatment of melanoma
WO2008002634A1 (fr) Utilisation d'inhibiteurs de la hdac pour le traitement des lymphomes

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted